GNPX News and Press, Genprex Inc. From 08/21/19

NetworkNewsWire Editorial Coverage : Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) ( GNPX Profi...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4 th Annual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019. Genpr...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy, to commercialization. Per...

Company’s recent performance sets path for future milestones, commercialization Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disc...

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successful...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to the American Medical Association&#x...

Company submits non-proprietary drug name selections to United States Adopted Names Council Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced it has initiated the first phase of branding its lead drug candidate, Oncoprex™ immunogene therapy...

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on ...

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on ...